Issue Cutting-Edge Therapies | Pharma's Almanac

Current Issue: Q2 2022

The Cutting-Edge Therapies Issue

Cutting-Edge Therapies

The Pharma’s Almanac editorial team is very excited to present our Q2 digital issue. This issue includes new content from our team and our colleagues at Nice Insight, as well as a large number of incredible subject matter experts from across the pharma/biopharma ecosystem, including drug discovery and development companies, life science industrials, technology providers, and contract development and manufacturing organizations. The diverse selection of topics touches on a huge spectrum of topics, united by the central thread of innovations that are ushering in the future of the industry.

Also In This Issue

ADCS

Improving the Therapeutic Index of ADCs with a Peptide Linker Technology

Although a growing number of antibody–drug conjugates (ADCs) have been approved as cancer therapeutics, the full promise of ADCs has yet to be fully realized, owing to issues with stability and the resulting toxic side effects. In this Q&A, Philipp Spycher, Ph.D., Chief Executive Officer and founder of Araris Biotech, discusses his company’s new peptide […]

Pharma 4.0

Applying an Advanced Pharma 4.0 Perspective to Design the Facility of the Future

Disruptive new biopharmaceutical CDMO Wheeler Bio is aiming to push the boundaries of biomanufacturing, designing a new facility that will advance along the Pharma 4.0 path and potentially set a new paradigm for applying risk-based thinking to introduce new concepts in manufacturing to support their clients. A panel of experts from Wheeler Bio, including Chief […]

Cell Line Development

Integrating Cell Line and CMC Development

Wheeler Bio hopes to change the paradigm for biologic drug discovery and development by providing open-source manufacturing processes and parallel integration between collaborating service providers to simplifying the pathway between drug discovery and scalable clinical biomanufacturing. More Disruptive Approaches Are Needed in the Pharma Services Industry Innovators of INDs (investigational new drugs) often face uncertainties […]

Column: M&A

Who’s Left to Acquire in CDMO Biomanufacturing? A Select Few.

Publicly funded biotechs have experienced drastic reductions in market value in recent months, while private companies continue to attract financing and are in-licensing technologies and expanding staff. With the slower economy, companies are often expected to drop early-stage projects to focus on more advanced lead candidates. These changes will impact demand for CDMO services beginning […]

Column: New Drug Watch

New Drug Watch: A Validation of the ‘Twincretin’ Approach to Type 2 Diabetes

The diabetes market is crowded but no one has nailed it yet — here’s why Eli Lilly’s new drug performs better than the competition. The most buzzed-about drug of Q2 2022 wasn’t a cell and gene therapy, mRNA platform, or CAR-T treatment. Instead of a rare disease being targeted — which has become the standard […]

Column: Investment

IPOs Have Not Recovered In 2022. When Will Biotech Bounce Back?

After a record-breaking year for biotech IPOs, the market slowdown that began in the second half of 2021 is here to stay. 2022 opened on a much cooler market, and the first quarter was the slowest in three years for new stock offerings.1 For young biotechs and their investors, life after the IPO cliff is […]

Column: Regulatory Spotlight

The Price of Pain: Acknowledging a Crisis and Encouraging an Alternative

Pain is nearly ubiquitous in the United States. According to a 2016 National Health Interview Survey featured by the CDC, one in five Americans — 50 million people — suffer from chronic pain. For 8% (19.6 million Americans) of chronic pain sufferers, this pain is so debilitating that it interferes with their daily lives.1 Groups […]

NFTs

Digital Frontiers: What NFTs Can Do for Pharma

2021 was the year that non-fungible tokens, or NFTs, received widespread attention on the internet and entered the corporate world in a significant way. Now, these crypto assets and the blockchain technology that makes them possible may have major real-world applications for supply chain GMP, patient data management, and the future of pharma. An Overview […]

Column: Supply Chain

Creating a More Resilient Pharmaceutical Supply Chain One Segment at a Time

Weaknesses within the highly complex and global pharmaceutical supply chain are not a new topic. However, the many conferences, working groups, and regulatory body discussions have led to minimal foundational change. Then, the COVID-19 pandemic made pharmaceutical supply chain vulnerabilities impossible to ignore, and much work has been done across many public and private organizations […]

Past Issues

View all Past Issues

The Advanced Therapeutics Issue

View Issue »

Issue #2 | Volume #5 | Q2 2019

The Outsourcing Issue

View Issue »

Issue #3 | Volume #6 | Q3 2020

The Business Development Issue

View Issue »

Issue #1 | Volume #5 | Q1 2019

The Role of Innovative Technologies

View Issue »

Issue #4 | Volume #2 | Q4 2016